Clinical trial
A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)
NCT01707147 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Regulatory Requirement Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus(SELINA Study)
- Lead sponsor
- Boehringer Ingelheim
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 16, 2012
- Completion date
- July 11, 2017
- Enrollment
- 3,219 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.